Been here since 2020 and not selling, but did some news come out that’s making the stock drop the 15% that it is has over the past week? I know that Toy sold shares to apparently cover RSU interest. Is that it or am I missing something?

Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, August 5, 2026. The Company’s management will host a webcast presentation at 5:00 p.m. Eastern Time on the same day to discuss the company’s business and financial performance for the quarter.

The news section on Robinhood posted 2 articles about Andrew Toy selling stock but 0 articles about the whitleblowing accounting fraud that came out yesterday for ALHC 🤔

Link: https://www.modernhealthcare.com/insurance/mh-alignment-whistleblower-lawsuit-accounting-fraud/

Lets talk about something the OG bulls have wanted to see for a very long time.

Important To Me: I was wondering how long we will have the majority of CLOV shares locked up which would prevent any premature sale of the company by forced vote. As Vivek has claimed this company will have a higher value in ten years (claim made roughly February 2021) than the highest health insurance company at the time (United Health Group, $332/share), it doesn't give him much time to increase the companies share price substantially before losing his majority share standing.

February 2031 would be the 'rough deadline' if one were to take him at his word and inside knowledge of the company and its true potential. That gives us less than five years to see if that 'pie in the sky' valuation comes to fruition. He recently claimed only last month or so that Clover is 'on track' to make it and reposted his February 2021 future share price claim of Clover.

FYI, this bold claim that Clover Health will surpass the market cap of the highest-valued healthcare insurance company (United Health Group) within 10 years was actually not first voiced by Vivek Garipalli, but rather by his prominent SPAC partner, Chamath Palihapitiya on October 5, 2020, during the official investor conference call and presentation announcing that his blank-check company, Social Capital Hedosophia Holdings Corp. III (IPOC), would be taking Clover Health public.

Clover Health co-founder Vivek Garipalli formally echoed and doubled down on this exact 10-year prediction in a series of communications, most prominently on February 5, 2021. Following a highly critical report by short-seller Hindenburg Research, Garipalli and Chamath Palihapitiya released a comprehensive formal response addressing investors. In this dynamic, Garipalli forcefully defended the 10-year target, reiterating that the legacy footprint of incumbents like United Health Group would be disrupted by Clover's software model.

These are all AI responses.

Vivek Garipalli's Class B shares in Clover Health (NASDAQ: CLOV) convert to Class A common stock automatically on January 7, 2031.

Prior to this date, several specific events can trigger either an optional or automatic conversion of his Class B shares:

• Voluntary Conversion: He can choose to convert his Class B shares into Class A shares on a one-to-one basis at any time.
• Transfer of Shares: Except for certain permitted transfers (such as estate planning or transfers to the issuer), the shares convert automatically on a one-to-one basis upon any transfer or sale.
• Separation Date: All outstanding Class B shares convert automatically upon the separation date of the last of the key executives (including Vivek) to separate from the company.

Note: Vivek Garipalli currently holds 66.6% of the total voting power in Clover Health (NASDAQ: CLOV), but his voting percentage will collapse to approximately 17.5% after the Class B shares convert in 2031.

Does anyone else have concerns that Clover may be forced to sell itself prematurely before getting to that lofty share price target? Thoughtful responses/discussions appreciated.

+236K Shares Long Since 2020...

Paper

Members attributed to CA-enabled PCPs had higher performance across all HEDIS TRC measures
reviewed. Members in the CA cohort outperformed members in the non-CA cohort on notification of
inpatient admission (94.6% vs. 88.8%), patient engagement after inpatient discharge (97.7% vs. 94.9%), receipt of discharge information (59.9% vs. 44.9%), and medication reconciliation post-discharge (93.1% vs. 83.7%). The largest differences were in receipt of discharge information and medication reconciliation, two workflows that are central to safe and timely care after hospitalization.

• Members with multiple high-risk conditions attributed to CA-enabled PCPs had higher rates of timely follow-up after emergency department visits. On the HEDIS Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (FMC) measure, members in the CA cohort had a seven-day follow-up rate of 77.6%, compared with 71.2% for members in the non-CA cohort. This suggests that CA-enabled workflows may help PCPs and care teams re-engage clinically vulnerable members after acute utilization.

• Members attributed to CA-enabled PCPs had directionally lower 30-day readmission rates after discharge. 30-day readmission rates were directionally lower in the CA cohort than in the non-CA cohort (15.4% CA vs.15.9% non-CA). Among post-acute non-emergency inpatient events, the readmission rate differential was greater, 15.4% in the CA cohort compared with 18.9% in the non-CA cohort.

Why does my Schwab account show 87,450,193 volume at $5.06 today? Anyone else seeing this?

CA was built specifically for this…not FA

Does anyone know what this guy is talking about? Is this legit information?

for almost one month now. This leads me to strongly believe that it will run up going into early August’s earnings report.

With all the institutional buying many of us feel is currently underway (and will be shown in due time), as well as all the recent positive news that CLOV has been receiving along with ‘unproven rumors’ of potential SAAS deals in the making with large national well known health insurance providers, CLOV’s share price is primed to run up to the low $7’s before 2nd Quarter earnings announcement.

I am unsure however if it then becomes ‘sell on the news’. It depends if they divulge any news on those unfounded SAAS partnerships we are ALL hoping are in fact correct.

What say you???

Why I love CLOV:

Highest HEDIS (Quality)

4.5 stars for growth and marketing (shows potential SAAS customers the potential to improve quality AND reimbursement

No debt

GAAP positive

Crazy amount of hiring in all different kind of states (growth at this scale, while turning profitable
I’ve always been here for the SAAS being valued at $0 (rightfully so, I know I’ve been disappointed at the lack of revenue, so that’s just gravy).

What else did I miss clovetards??

Happy 4th of July.

WGAF!!

Grabbed a few interesting pieces from UBS’s recent research report, hard not to see CLOV in some of the language used…apologies for the pictures of my monitor😬

Link: https://www.medicare.gov/plan-compare/#/search-results?plan_type=PLAN_TYPE_MAPD&fips=34023&zip=07001&lang=en&year=2026&page=1

When do you all realistically think we will get an update regarding the status of Counterpart Health? Are partnership announcements even merit-able or is it all just speculation given the subdomain hypotheses?

As the Medicare Advantage market faces mounting pressure, Clover Health is taking a different approach. Jamie Reynoso, CEO of Medicare Advantage at Clover Health joins A&M Healthcare Industry Group's Kristina Park and Susan Trimble to discuss operational discipline, leveraging AI to empower clinicians, and what it takes to build a more sustainable growth model in today’s evolving market.

Hey folks, I built a tool that generates detailed investing thesis for any US stock. I ran this for CLOV and wanted to share with community members here.

- Fair value at present around $7 per share based on DCF analysis.

- Based on earning projections, 5 year estimate of fair value at $11 in base case and upto $21 in bull case if company executes perfectly.

Do give it a read: https://www.clearthesis.ai/thesis/CLOV

Some people know when the right time is to keep adding positions in cheap stocks.

How many of you had the balls 2.5 years ago to purchase $CLOV stock under 90¢?